NCT07685405

Brief Summary

The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
20mo left

Started Apr 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress15%
Apr 2026Apr 2028

Study Start

First participant enrolled

April 15, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 29, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 6, 2026

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2028

Last Updated

July 6, 2026

Status Verified

June 1, 2026

Enrollment Period

2 years

First QC Date

June 29, 2026

Last Update Submit

June 29, 2026

Conditions

Sarcoma, Ewing

Outcome Measures

Primary Outcomes (1)

  • characterisation of circulating biomarkers

    search for circulating biomarkers from blood samples taken at three different time points

    at baseline (time 0); before surgery; after 6 months from surgery

Study Arms (2)

oncological subject

Other: 3 blood samples

non-oncological subjects

Other: one blood sample

Interventions

one blood sampleOTHER

non onco

non-oncological subjects
3 blood samplesOTHER

onco

oncological subject

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study aims to enroll patients of any gender who are being treated at the Rizzoli Orthopedic Institute in the following departments: Orthopedic and Traumatology Clinic III (with a primary focus on oncology), General and Thoracic Surgery (for both cancer and non-cancer patients), and Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies (for cancer patients only).

You may qualify if:

  • Male and female patients of any age diagnosed with Ewing sarcoma.
  • Signed, study-specific informed consent form for the BIOVES study (cancer patients)
  • Male and female patients of legal age without a cancer diagnosis.
  • Signed, study-specific informed consent form for the BIOVES study (non-cancer patients)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle

Bologna, BO, 40136, Italy

RECRUITING

MeSH Terms

Conditions

Sarcoma, Ewing

Condition Hierarchy (Ancestors)

OsteosarcomaNeoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcoma

Central Study Contacts

Katia Scotlandi, MSc

CONTACT

39 051 6366760katia.scotlandi@ior.it

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2026

First Posted

July 6, 2026

Study Start

April 15, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Last Updated

July 6, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations

IT(1)